AR and prostate carcinoma: Lineage enrichment analysis revealed that enhancer-driven AR-positive prostate cancer, neuroblastoma, rhabdoid tumor and acute myeloid leukemia51–53 were among the most sensitive to CBPD-409 treatment (Fig. 5e).